Cargando…
Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis
Background. The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly effective TNF-α inhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not uncommon. Thus, laboratory biomarkers of disease...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129379/ https://www.ncbi.nlm.nih.gov/pubmed/25136144 http://dx.doi.org/10.1155/2014/236060 |
_version_ | 1782330227369705472 |
---|---|
author | Cordiali-Fei, P. Bianchi, L. Bonifati, C. Trento, E. Ruzzetti, M. Francesconi, F. Bultrini, S. D'Agosto, G. Bordignon, V. Francavilla, V. Tripiciano, A. Chiricozzi, A. Campione, E. Cavallotti, C. Orlandi, A. Berardesca, E. Di Carlo, A. Chimenti, S. Ensoli, F. |
author_facet | Cordiali-Fei, P. Bianchi, L. Bonifati, C. Trento, E. Ruzzetti, M. Francesconi, F. Bultrini, S. D'Agosto, G. Bordignon, V. Francavilla, V. Tripiciano, A. Chiricozzi, A. Campione, E. Cavallotti, C. Orlandi, A. Berardesca, E. Di Carlo, A. Chimenti, S. Ensoli, F. |
author_sort | Cordiali-Fei, P. |
collection | PubMed |
description | Background. The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly effective TNF-α inhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not uncommon. Thus, laboratory biomarkers of disease progression/therapeutic efficacy may greatly help in the clinical management of psoriasis. Aims. To identify laboratory biomarkers for clinical management and therapeutic monitoring of psoriasis. Methods. An observational study performed on 59 patients, presenting moderate to severe psoriasis, undergoing treatment with anti-TNF-α agents (etanercept, adalimumab, and infliximab). Soluble and cellular immune/inflammatory parameters were assessed at baseline and after 12 and 24 weeks of treatment. Results. Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after 24 weeks. IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of CLA+ T cells and an increase of Treg lymphocytes. T, B, and NK cell subsets and T cell response to recall antigens did not show any evidence of immune suppression. Conclusions. Immune/inflammatory parameters including IL-6 and IL-22, CLA+ T cells, and Treg lymphocytes may prove to be valuable laboratory tools for the clinical and therapeutic monitoring of psoriasis. |
format | Online Article Text |
id | pubmed-4129379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-41293792014-08-18 Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis Cordiali-Fei, P. Bianchi, L. Bonifati, C. Trento, E. Ruzzetti, M. Francesconi, F. Bultrini, S. D'Agosto, G. Bordignon, V. Francavilla, V. Tripiciano, A. Chiricozzi, A. Campione, E. Cavallotti, C. Orlandi, A. Berardesca, E. Di Carlo, A. Chimenti, S. Ensoli, F. Mediators Inflamm Clinical Study Background. The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly effective TNF-α inhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not uncommon. Thus, laboratory biomarkers of disease progression/therapeutic efficacy may greatly help in the clinical management of psoriasis. Aims. To identify laboratory biomarkers for clinical management and therapeutic monitoring of psoriasis. Methods. An observational study performed on 59 patients, presenting moderate to severe psoriasis, undergoing treatment with anti-TNF-α agents (etanercept, adalimumab, and infliximab). Soluble and cellular immune/inflammatory parameters were assessed at baseline and after 12 and 24 weeks of treatment. Results. Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after 24 weeks. IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of CLA+ T cells and an increase of Treg lymphocytes. T, B, and NK cell subsets and T cell response to recall antigens did not show any evidence of immune suppression. Conclusions. Immune/inflammatory parameters including IL-6 and IL-22, CLA+ T cells, and Treg lymphocytes may prove to be valuable laboratory tools for the clinical and therapeutic monitoring of psoriasis. Hindawi Publishing Corporation 2014 2014-07-20 /pmc/articles/PMC4129379/ /pubmed/25136144 http://dx.doi.org/10.1155/2014/236060 Text en Copyright © 2014 P. Cordiali-Fei et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Cordiali-Fei, P. Bianchi, L. Bonifati, C. Trento, E. Ruzzetti, M. Francesconi, F. Bultrini, S. D'Agosto, G. Bordignon, V. Francavilla, V. Tripiciano, A. Chiricozzi, A. Campione, E. Cavallotti, C. Orlandi, A. Berardesca, E. Di Carlo, A. Chimenti, S. Ensoli, F. Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis |
title | Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis |
title_full | Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis |
title_fullStr | Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis |
title_full_unstemmed | Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis |
title_short | Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis |
title_sort | immunologic biomarkers for clinical and therapeutic management of psoriasis |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129379/ https://www.ncbi.nlm.nih.gov/pubmed/25136144 http://dx.doi.org/10.1155/2014/236060 |
work_keys_str_mv | AT cordialifeip immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT bianchil immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT bonifatic immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT trentoe immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT ruzzettim immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT francesconif immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT bultrinis immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT dagostog immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT bordignonv immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT francavillav immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT tripicianoa immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT chiricozzia immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT campionee immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT cavallottic immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT orlandia immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT berardescae immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT dicarloa immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT chimentis immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis AT ensolif immunologicbiomarkersforclinicalandtherapeuticmanagementofpsoriasis |